Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
Helsinki Institute of Life Science (HiLIFE), University of Helsinki, FI-00014, Helsinki, Finland.
Drug Deliv Transl Res. 2021 Apr;11(2):353-372. doi: 10.1007/s13346-021-00924-7. Epub 2021 Feb 17.
The current situation, heavily influenced by the ongoing pandemic, puts vaccines back into the spotlight. However, the conventional and traditional vaccines present disadvantages, particularly related to immunogenicity, stability, and storage of the final product. Often, such products require the maintenance of a "cold chain," impacting the costs, the availability, and the distribution of vaccines. Here, after a recall of the mode of action of vaccines and the types of vaccines currently available, we analyze the past, present, and future of vaccine formulation. The past focuses on conventional formulations, the present discusses the use of nanoparticles for vaccine delivery and as adjuvants, while the future presents microneedle patches as alternative formulation and administration route. Finally, we compare the advantages and disadvantages of injectable solutions, nanovaccines, and microneedles in terms of efficacy, stability, and patient-friendly design. Different approaches to vaccine formulation development, the conventional vaccine formulations from the past, the current development of lipid nanoparticles as vaccines, and the near future microneedles formulations are discussed in this review.
当前的形势受到持续大流行的严重影响,使疫苗重新成为焦点。然而,传统疫苗存在缺点,特别是在免疫原性、最终产品的稳定性和储存方面。通常情况下,此类产品需要维持“冷链”,这会影响疫苗的成本、供应和分配。在这里,我们回顾了疫苗的作用模式和目前可用的疫苗类型,分析了疫苗配方的过去、现在和未来。过去侧重于传统配方,现在讨论了纳米颗粒在疫苗传递和佐剂中的应用,而未来则提出了微针贴片作为替代配方和给药途径。最后,我们比较了注射溶液、纳米疫苗和微针在疗效、稳定性和患者友好设计方面的优缺点。本综述讨论了疫苗配方开发的不同方法、过去的传统疫苗配方、目前作为疫苗的脂质纳米颗粒的开发以及不久的将来的微针配方。
Drug Deliv Transl Res. 2021-4
Ther Deliv. 2017-6
Curr Med Chem. 2017
Micromachines (Basel). 2021-4-14
Pharm Res. 2017-7-17
Hum Vaccin Immunother. 2021-1-2
Adv Drug Deliv Rev. 2021-12
Adv Healthc Mater. 2018-12-10
Curr Top Microbiol Immunol. 2009
Int J Nanomedicine. 2025-5-7
Vaccines (Basel). 2025-3-5
Biology (Basel). 2024-11-27
Front Cell Infect Microbiol. 2024-12-20
Mol Biomed. 2024-11-11
Drug Deliv Transl Res. 2024-10
ACS Biomater Sci Eng. 2020-2-10
AAPS PharmSciTech. 2020-8-5
Expert Opin Ther Pat. 2020-6-7
Science. 2020-4-3